Inflazome, a joint spin-out company from Trinity College Dublin and Australia’s University of Queensland in 2016, develops orally available treatments for a range of inflammatory and neurodegenerative diseases. In 2020, Inflazome was acquired by global pharma giant Roche in a €380m deal which remains one of the largest biotech deals in Australian and Irish history. The acquisition has heightened the global profile of Irish science and expertise as well as yielding significant financial returns to the Irish exchequer.
The Innovation Office at Trinity College Dublin supported the company at the time of foundation by ensuring a co-operative relationships between the University and UniQuest in Australia and worked to negotiate an effective licence that facilitated the foundation of the company and was structured in such a way as to subsequently make for a smooth acquisition by Roche.